Healthy Skepticism AdWatch (Australia)
AdWatch illuminates the logical, psychological and pharmacological techniques used in drug advertisements.
August 2007
Criticism of Adwatch on Avandia (rosiglitazone)
This issue has been written in response to a subscriber's comments regarding the March AdWatch about GlaxoSmithKline's advertising of rosiglitazone (Avandia) in Australia.
June 2007
Celebrex (celecoxib) from Pfizer
Is consumer health information from drug companies trustworthy? This AdWatch analyses an advertorial by Pfizer published in the Australian edition of the Readers Digest in March 2007.
March 2007
Avandia (rosiglitazone) from GlaxoSmithKline
Do not ADOPT rosiglitazone as first-line diabetes treatment.
September 2006
Efexor Tetrapack (venlafaxine) from Wyeth
Antidepressants are not sweets.
July 2006
Lipidil (fenofibrate) from Solvay/Fournier
'Don't give him the usual treatment'.
April 2006
Estelle-35ED (cyproterone-oestradiol) from Douglas
Estelle-35ED (cyproterone-oestradiol) (Douglas)
She needs safe and reliable contraception, not a treatment for severe acne!
August 2004
Feedback on Micardis Plus (telmisartan plus hydrochlorothiazide) from Boehringer Ingelheim
This report is based on feedback from 52 participants of whom 58% were doctors and 17% pharmacists.
June 2004
Micardis Plus (telmisartan plus hydrochlorothiazide) from Boehringer Ingelheim
"The early morning danger zone":
Micardis Plus (telmisartan plus hydrochlorothiazide) from Boehringer Ingelheim
April 2004
Dialogue on Nexium (esomeprazole) from AstraZeneca
Correspondence between Healthy Skepticism and AstraZeneca regarding the advertising of Nexium.
March 2004
Feedback on Augmentin (amoxicillin with potassium clavulanate) from GlaxoSmithKline
This report is based on feedback from 107 participants in the AdWatch on Augmentin (amoxycillin with potassium clavulanate) from GSK.
February 2004
Augmentin (amoxicillin with potassium clavulanate) from GlaxoSmithKline
"Take a closer look"
December 2003
Feedback on Nexium (esomeprazole) from AstraZeneca
This report is based on feedback from 142 people who participated in AdWatch during 26 September to 13 December 2003.
October 2003
Nexium (esomeprazole) from AstraZeneca
Appealing to our desire for power.
